Alflutinib Recruiting Phase 2 Trials for EGFR L861Q / EGFR S768I / EGFR G719X / Non-Small Cell Lung Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT05548348First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon Mutation